デフォルト表紙
市場調査レポート
商品コード
1612567

生物製剤市場:供給源、製品、適応症、エンドユーザー別-2025-2030年の世界予測

Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 189 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
生物製剤市場:供給源、製品、適応症、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

生物製剤市場は、2023年に4,057億6,000万米ドルと評価され、2024年には4,305億9,000万米ドルに達すると予測され、CAGR 6.39%で成長し、2030年には6,263億4,000万米ドルに達すると予測されています。

生物製剤は、製薬業界の中で急速に拡大しているセグメントで、ワクチン、血液成分、遺伝子治療、モノクローナル抗体など、生物由来の多様な製品を包含しています。慢性疾患の増加、バイオテクノロジーの進歩、標的治療の必要性は、生物製剤の必要性を強調しています。その用途は、がん、関節リウマチ、多発性硬化症などの疾患の治療に及び、病院、研究機関、専門クリニックで使用されています。主な成長要因としては、遺伝子工学や細胞治療における継続的な技術革新、迅速な医薬品承認を促進する強固な規制支援などが挙げられます。さらに、製薬会社とバイオテクノロジー新興企業との提携は、特に精密医療とバイオシミラー(より安価な代替治療薬を提供する医薬品クラス)において画期的な成果をもたらしています。個別化された治療法の開発や、需要増に対応するための生産拡張性の強化にこそ治療機会があります。しかし、生物製剤市場は、高い研究開発コスト、複雑な製造プロセス、厳しい規制要件などの制約に直面しており、市場移行までの時間が長期化することが多いです。重要な課題は、製品の安定性と一貫性の維持です。市場参入企業にとって革新的な分野には、バイオプロセス技術の最適化や人工知能の活用による創薬・開発の効率化などがあります。コールドチェーンの限界を克服するには、保管・流通のための強固なインフラも不可欠です。市場はダイナミックで、参入障壁が高い一方で、イノベーションに成功すれば高い報酬が得られるという特徴があります。企業が成功するためには、技術共有のための戦略的提携、研究開発の効率化、アンメット・メディカル・ニーズのある新興市場の開拓に注力すべきです。このような情勢を乗り切るには、最先端の科学的発見と現実的なサプライチェーンマネジメントのバランスを取ることが必要です。

主な市場の統計
基準年[2023] 4,057億6,000万米ドル
推定年[2024] 4,305億9,000万米ドル
予測年[2030] 6,263億4,000万米ドル
CAGR(%) 6.39%

市場力学:急速に進化する生物製剤市場の主要市場インサイトを公開

生物製剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の慢性疾患の有病率の上昇
    • 低侵襲手術に対するニーズと嗜好の高まり
  • 市場抑制要因
    • 生物製剤に関連する治療費の高騰
  • 市場機会
    • 慢性疾患の治療を改善するバイオマテリアルの継続的進歩
    • 生物製剤に関連する製造施設の拡大の高まり
  • 市場の課題
    • 生物製剤の複雑な製造の可能性

ポーターのファイブフォース:生物製剤市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、生物製剤市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:生物製剤市場における外部からの影響の把握

外部マクロ環境要因は、生物製剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生物製剤市場における競合情勢の把握

生物製剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生物製剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生物製剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生物製剤市場における成功への道筋を描く

生物製剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で慢性疾患の罹患率が上昇
      • 低侵襲手術に対するニーズと好みの高まり
    • 抑制要因
      • 生物製剤に関連する治療費の高騰
    • 機会
      • 慢性疾患の治療を改善する生体材料の継続的な進歩
      • 生物製剤に関連する製造施設の拡大
    • 課題
      • 生物製剤の複合製造の可用性
  • 市場セグメンテーション分析
    • 出典:哺乳類細胞はより大きく複雑なタンパク質を生産するのに適している
    • 適応症:COVID-19パンデミックとがん研究の進化によって推進される腫瘍学および感染症における継続的なイノベーション
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 生物製剤市場:ソース別

  • 哺乳類
  • 微生物

第7章 生物製剤市場:製品別

  • アンチセンスおよびRNAi治療薬
  • モノクローナル抗体
  • 組み換えホルモンまたはタンパク質
  • ワクチン

第8章 生物製剤市場適応症別

  • 心血管疾患
  • 血液疾患
  • 免疫疾患
  • 感染症
  • 腫瘍学

第9章 生物製剤市場:エンドユーザー別

  • 外来手術センター
  • 病院

第10章 南北アメリカの生物製剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の生物製剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの生物製剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • FDAが初のトシリズマブバイオシミラーTOFIDENCEを承認、自己免疫疾患治療へのアクセスを向上
    • イーライリリー、アイルランドの生物製剤製造施設への投資を拡大
    • サンドス、スロベニアの新施設への大規模投資を発表
  • 戦略分析と提言

企業一覧

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioPharm Laboratories, LLC
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Inc.
図表

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY ANTISENSE & RNAI THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT HORMONES OR PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-4302AC72200D

The Biologics Market was valued at USD 405.76 billion in 2023, expected to reach USD 430.59 billion in 2024, and is projected to grow at a CAGR of 6.39%, to USD 626.34 billion by 2030.

Biologics, a rapidly expanding segment within the pharmaceutical industry, encompass a diverse range of products derived from living organisms, such as vaccines, blood components, gene therapy, and monoclonal antibodies. The increasing prevalence of chronic diseases, advancements in biotechnology, and the need for targeted therapies underscore the necessity of biologics. Their applications span across treating diseases like cancer, rheumatoid arthritis, and multiple sclerosis, serving hospitals, research institutions, and specialty clinics. Key growth influencers include ongoing innovations in genetic engineering and cell therapy, alongside robust regulatory support facilitating expedited drug approvals. Additionally, partnerships between pharmaceutical companies and biotech startups are yielding breakthroughs, particularly in precision medicine and biosimilars-a class of drugs offering more affordable therapeutic alternatives. Opportunities lie in developing personalized treatment approaches and enhancing production scalability to meet growing demand. However, the biologics market faces limitations such as high R&D costs, complex manufacturing processes, and stringent regulatory requirements which often prolong time-to-market transitions. A key challenge is maintaining product stability and consistency. For market players, innovative areas include optimizing bioprocessing techniques and harnessing artificial intelligence to streamline drug discovery and development. Robust infrastructure for storage and distribution is also vital to overcoming cold chain limitations. The market is dynamic, characterized by high barriers to entry but also high rewards for successful innovation. To thrive, businesses should focus on strategic alliances for technology sharing, enhancing R&D efficiencies, and exploring emerging markets with unmet medical needs. Navigating the biologics landscape requires balancing cutting-edge scientific discovery with pragmatic supply chain management-a challenge that, if met, promises significant growth potential in improving global health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 405.76 billion
Estimated Year [2024] USD 430.59 billion
Forecast Year [2030] USD 626.34 billion
CAGR (%) 6.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Market

The Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases worldwide
    • Growing need and preference for minimally invasive procedures
  • Market Restraints
    • High cost of treatment associated with biologics
  • Market Opportunities
    • Ongoing advancements in biomaterials improving the treatment of chronic disorders
    • Rising expansion of manufacturing facilities associated with biologics
  • Market Challenges
    • Availability of complex manufacturing of biologics

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Market

A detailed market share analysis in the Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Market

A strategic analysis of the Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Product, market is studied across Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins, and Vaccines.
  • Based on Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, Infectious Diseases, and Oncology.
  • Based on End-user, market is studied across Ambulatory Surgical Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need and preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in biomaterials improving the treatment of chronic disorders
      • 5.1.3.2. Rising expansion of manufacturing facilities associated with biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of complex manufacturing of biologics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Mammalian cells are preferable for producing larger and more complex proteins
    • 5.2.2. Indication: Ongoing innovations in oncology and infectious diseases driven by the COVID-19 pandemic and cancer research's evolution
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Market, by Source

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Microbial

7. Biologics Market, by Product

  • 7.1. Introduction
  • 7.2. Antisense & RNAi Therapeutics
  • 7.3. Monoclonal Antibodies
  • 7.4. Recombinant Hormones or Proteins
  • 7.5. Vaccines

8. Biologics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Infectious Diseases
  • 8.6. Oncology

9. Biologics Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals

10. Americas Biologics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
    • 13.3.2. Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
    • 13.3.3. Sandoz Announces Major Investment in New Biologics Facility in Slovenia
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Becton, Dickinson and Company
  • 6. Biogen Inc.
  • 7. BioPharm Laboratories, LLC
  • 8. Bristol Myers Squibb Company
  • 9. Catalent, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Innovent Biologics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Thermo Fisher Scientific Inc.
  • 21. Vertex Pharmaceuticals Inc.